Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and Raltegravir

This study has been completed.
Raltegravir is provided by Merck.
Information provided by:
Tibotec Pharmaceuticals, Ireland Identifier:
First received: January 7, 2011
Last updated: June 23, 2011
Last verified: June 2011
The purpose of this study is to investigate the effect of steady-state concentrations of raltegravir (administered as 400 mg, twice daily) on the steady-state pharmacokinetics of TMC278 (25 mg, once daily), and vice versa. Steady state is a term that means that the drug has been given long enough so that the plasma levels will remain at about the same level with each subsequent dose. TMC278 is being investigated for the treatment of human immunodeficiency virus (HIV) infection. Raltegravir is a commercially available antiretroviral drug for treatment of HIV infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body.

Condition Intervention Phase
HIV Infections
Drug: TMC278
Drug: Raltegravir
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC278 25 mg q.d. and Raltegravir 400 mg b.i.d.

Resource links provided by NLM:

Further study details as provided by Tibotec Pharmaceuticals, Ireland:

Primary Outcome Measures:
  • Change in exposure to TMC278 following co-administration with raltegravir and vice versa [ Time Frame: Measured on Days 5, 12, 13, 14, 15, and 16 (TrtC). Reference for exposure to raltegravir only (TrtB), measured on Days 1, 2, 3, and 4. Reference for exposure to TMC278 only (TrtA), measured on Days 1, 8, 9, 10, 11, and 12. ]

Secondary Outcome Measures:
  • Number of participants with adverse events as a measure of safety and tolerability - TMC278 and raltegravir. [ Time Frame: 97 to 99 days (until and including last safety follow-up visit) ]

Enrollment: 24
Study Start Date: February 2011
Study Completion Date: May 2011
Arms Assigned Interventions
Experimental: 001
TMC278 One 25 mg tablet once daily for 11 days (TrtA and C)
Drug: TMC278
One 25 mg tablet, once daily, for 11 days (TrtA and C)
Experimental: 002
Raltegravir One 400 mg tablet twice daily for 4 days (Trt B) and for 11 days (TrtC)
Drug: Raltegravir
One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)

Detailed Description:
TMC278 is being investigated for treatment of HIV infection. Raltegravir is a commercially available HIV drug. The results of this study will provide dosing recommendations for coadministration of TMC278 and raltegravir in HIV-infected patients. This is a Phase I, open-label (both participant and investigator know the name of the medication given at a certain moment), randomized (sequence of treatment with study medications is assigned by chance), crossover trial in 24 healthy volunteers to investigate the pharmacokinetic interaction between TMC278 and raltegravir, at steady state. The study will consist of 3 phases: a screening phase, an open-label treatment phase consisting of 2 treatment periods, and end-of-study or withdrawal assessments. The duration of participation in the study for an individual participant will be up to 3 months (including screening). All participants will be randomly assigned to 1 of 2 possible treatment sequences and receive the following 2 treatments (Trt-s): TMC278 25 mg, once daily, alone for 11 days (TrtA), and raltegravir 400 mg, twice daily, alone for 4 days immediately followed by coadministration of the same raltegravir dose plus TMC278 25 mg, once daily, for 11 days (TrtB+C). There will be a washout period (a period where no study drug will be taken in view of having all the medication eliminated from the body before starting a new treatment) of at least 14 days between last intake of study medication in one session and first intake of study medication in the subsequent session. Pharmacokinetic profiles of both compounds will be determined through blood samples taken at regular intervals during the study. Safety and tolerability will be assessed during the study period and in follow-up. Blood and urine samples, electrocardiogram (ECG) and vital signs (blood pressure and heart rate) will be taken at screening, before medication intake in TrtA on Days 1, 11, and 12 (Day 12 is without ECG), in TrtB+C on Days 1, 4, 5, 15, and 16 (Day 16 is without ECG) and at the 2 follow-up visits (but without ECG) at 1 week and 4 weeks after last dose of study medication in the last session. A physical examination will be performed at screening, on Days 10 and 12 of TrtA, on Days 3, 14, and 16 of TrtB+C, and at both follow-up visits. Healthy volunteers will stay overnight in the study center for 3 nights in TrtA and for 5 nights in TrtB+C. Each volunteer will receive in a randomized order 2 treatments, minimum 14 days apart from each other. TrtA is TMC278 25 mg, once daily, for 11 days. TrtB+C is raltegravir 400 mg, twice daily, alone for first 4 days (TrtB) followed by coadministration of 400 mg raltegravir, twice daily, and TMC278 25 mg, once daily, on Days 5 to 15 (TrtC).

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, based on physical examination, medical history, vital signs, ECG, blood biochemistry, hematology and urinalysis
  • Body Mass Index of 18 to 30.0 kg/m2
  • Non-smoking for at least 3 months prior to screening
  • Women must be postmenopausal for at least 2 years, or be surgically sterile.

Exclusion Criteria:

  • Infected with Hepatitis A, B, or C Virus
  • Infected with human immunodeficiency virus (HIV)
  • History of clinically relevant hearth rhythm disturbances
  • Having previously participated in more than 1 study with raltegravir, TMC125, TMC120 and/or TMC278 or having developed rash, erythema or urticaria while participating in a trial with aforementioned compounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01288755

Sponsors and Collaborators
Tibotec Pharmaceuticals, Ireland
Raltegravir is provided by Merck.
Study Director: Tibotec Pharmaceuticals Clinical Trial Tibotec Pharmaceutical Limited
  More Information

Responsible Party: Compound Development Team Leader, Tibotec Pharmaceuticals, Ireland Identifier: NCT01288755     History of Changes
Other Study ID Numbers: CR017773
Study First Received: January 7, 2011
Last Updated: June 23, 2011

Keywords provided by Tibotec Pharmaceuticals, Ireland:

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Raltegravir Potassium
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
HIV Integrase Inhibitors
Integrase Inhibitors processed this record on May 23, 2017